Submacular hemorrhage secondary to polypoidal choroidal vasculopathy
Conditions
Interventions
Experimental group:Posterior approach vitrectomy combined with subretinal injection of TPA and intravitreal injection of anti-VEGF drugs for treatment
Sponsors
Yuebei People’s Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age range of patients: 40 - 90 years old; 2. Onset time of submacular hemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV): within 3 days to 1 month; 3. Meeting the diagnostic criteria for SMH secondary to PCV through ultra-widefield fundus imaging, optical coherence tomography scanning, or fundus angiography (fluorescein fundus angiography [FFA], indocyanine green angiography [ICGA]); 4. SMH larger than 1 disc diameter; 5. No refractive media opacities affecting fundus examination; 6. Having signed the informed consent form and being willing to undergo follow-up according to the time specified in the trial.
Exclusion criteria
Exclusion criteria: 1. Patients with any of the following eye diseases: (1). Patients with diseases such as corneal opacity and corneal leukoma that affect visual acuity assessment; (2). In addition to PCV, the target eye has other ophthalmic conditions that cause retinal/macular lesions, visual acuity changes, or SMH (such as pathological myopia, retinal vein occlusion [RVO], diabetic retinopathy [DR], macular hole, macular splitting, macular atrophy, etc.); (3). Any eye with active ocular infections (such as blepharitis, keratitis, scleritis, conjunctivitis, etc.); (4). The target eye has glaucoma or a history of glaucoma filtering surgery; (5). Cataract in the target eye may affect the examination or the judgment of research results, or the patient plans to undergo cataract surgery within the next month; (6). If the investigator deems that you are not suitable for participating in this study, including your inability or unwillingness to comply with the protocol requirements, you will not be eligible for this study. 2. Those who have any of the following eye treatments: (1) Received intravitreal anti-VEGF drug injection (such as ranibizumab, aflibercept, conbercept, faricimab, etc.) or intraocular steroid injection (triamcinolone acetonide, dexamethasone implant) within the past 1-3 months; (2) Received photodynamic therapy (PDT) and retinal laser photocoagulation within the past 6 months; (3) History of vitrectomy or other internal eye surgery (such as complex cataract surgery) in the past 6 months; (4) Participating in other clinical trials or receiving novel therapies (e.g., gene therapy, targeted drugs) 3. Patients with any of the following systemic diseases: (1) Those who are allergic to mydriatic drugs, local anesthetics, contrast agents, therapeutic protein products, etc.; (2) Patients with coagulation dysfunction; (3) Those with severe heart, liver, and kidney insufficiency, and those who cannot tolerate surgery; (4) Women who have recently been preparing to give birth or are pregnant and lactating; (5) Patients with uncontrollable systemic organic lesions or functional abnormalities (such as blood pressure, blood glucose) or in the acute systemic infection phase (requiring oral, intramuscular or intravenous administration).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uncorrected visual acuity;Best corrected visual acuity;Macular foveal retinal thickness;Pigment epithelial detachment height;Macular volume;Macular hemorrhage clearance rate; | — |
Countries
China
Contacts
Public ContactLiao Wu
Yuebei People’s Hospital
Outcome results
None listed